1. Absorption
Absorption is the transfer of a drug from its site of administration into the systemic circulation. The rate and extent of absorption determine how quickly a therapeutic concentration is reached and how much of the dose becomes available for pharmacologic action. Key determinants include:
- Physicochemical properties solubility, ionization state, and molecular size affect membrane permeability.
- Formulation factors immediaterelease tablets, sustainedrelease capsules, or parenteral solutions modify dissolution and release.
- Route of administration oral, sublingual, intramuscular, intravenous, transdermal, and inhalation each have distinct absorption profiles.
- Gastrointestinal environment pH, gastric emptying time, and presence of food can enhance or impede oral drug uptake.
The bioavailability (F) of a drug is expressed as a fraction of the administered dose that reaches systemic circulation unchanged. Intravenous administration has 100% bioavailability, whereas oral drugs rarely exceed 80% because of firstpass metabolism and incomplete absorption.
2. Distribution
After entering the blood, a drug disperses throughout body fluids and tissues. Distribution is influenced by blood flow, tissue affinity, and binding to plasma proteins (primarily albumin and 1acid glycoprotein). Two parameters commonly describe this phase:
- Volume of distribution (Vd) a theoretical volume that relates the total amount of drug in the body to the concentration in plasma. A high Vd indicates extensive tissue binding; a low Vd suggests the drug remains largely within the vascular compartment.
- Fraction unbound (fu) only the unbound fraction is pharmacologically active and capable of crossing cell membranes.
Special considerations include the bloodbrain barrier, which restricts entry of many molecules into the central nervous system, and the placenta, which permits certain drugs to cross from mother to fetus. Age, body composition, and disease states (e.g., edema or hypoalbuminemia) can markedly alter distribution patterns.
3. Metabolism
Metabolism converts parent compounds into more watersoluble metabolites, facilitating elimination. The liver is the principal site of drug biotransformation, although the intestine, kidneys, lungs, and even skin contribute to the metabolic capacity. PhaseI reactions (oxidation, reduction, hydrolysis) are predominantly catalyzed by cytochromeP450 enzymes, while PhaseII reactions (conjugation) involve glucuronidation, sulfation, and acetylation.
Enzymatic activity varies widely among individuals due to genetics, age, diet, and exposure to inducers or inhibitors. For example, CYP2D6 poor metabolizers may experience drug accumulation and toxicity, whereas CYP3A4 inducers such as rifampin can lower plasma concentrations of coadministered drugs. Metabolites themselves can be active (e.g., codeine morphine) or toxic (e.g., acetaminophen Nacetylpbenzoquinone imine).
4. Excretion
Excretion eliminates the parent drug and its metabolites from the body. The kidneys are the primary route for most drugs, using glomerular filtration, tubular secretion, and reabsorption. Renal clearance (Clrenal) is a valuable predictor of dosing adjustments in patients with impaired kidney function.
Other routes include biliary excretion into the feces, pulmonary exhalation of volatile agents, and, less commonly, sweat, saliva, or breast milk. The halflife (t) of a drugthe time required for plasma concentration to decline by 50%is derived from clearance and Vd, and it guides dosing intervals and steadystate achievement.
5. Factors That Modify Pharmacokinetics
Multiple patientspecific and external variables can influence each pharmacokinetic phase:
- Age Neonates have immature metabolic pathways; elderly patients often exhibit reduced renal clearance.
- Genetics Polymorphisms in CYP enzymes, transporters (e.g., Pgp), and conjugating enzymes alter drug handling.
- Comorbidities Liver cirrhosis, heart failure, and renal disease shift distribution volumes and clearance rates.
- Drugdrug interactions Enzyme inducers accelerate metabolism, while inhibitors prolong exposure.
- Lifestyle factors Smoking induces CYP1A2; grapefruit juice inhibits CYP3A4; diet can affect absorption.
- Route and formulation Switching from oral to intravenous bypasses firstpass loss; sustainedrelease formulations prolong absorption.
6. Clinical Relevance of Pharmacokinetics
Understanding pharmacokinetic principles is essential for optimal drug therapy. Key applications include:
- Dosing adjustments Calculating renaladjusted doses in chronic kidney disease prevents accumulation and toxicity.
- Therapeutic drug monitoring (TDM) Measuring plasma concentrations of narrowtherapeuticindex drugs (e.g., vancomycin, lithium) ensures efficacy while avoiding adverse effects.
- Drug development Early PK studies guide leadcompound selection, formulation design, and dosing regimen planning.
- Personalized medicine Pharmacogenetic testing informs selection of agents that are metabolized by specific CYP isoforms.
- Risk mitigation Predicting drugdrug interactions helps clinicians avoid dangerous plasma level spikes or subtherapeutic exposures.
7. Summary
Pharmacokinetics describes the journey of a drug through four interconnected processes: absorption, distribution, metabolism, and excretion (ADME). Each step is shaped by the drugs physicochemical attributes, patient characteristics, and external influences such as coadministered medications and lifestyle choices. By quantifying how much drug reaches its target site, how long it stays active, and how it is cleared, clinicians can tailor therapy to achieve maximal benefit with minimal risk.
Continued advances in analytical techniques, population PK modeling, and pharmacogenomics are expanding our ability to predict individual responses and to design smarter dosing regimens. In practice, the integration of pharmacokinetic knowledge with clinical judgment remains a cornerstone of safe, effective, and personalized pharmacotherapy.
For further reading, consider resources such as FDA guidance on PK/PD, the textbook Goodman & Gilmans The Pharmacological Basis of Therapeutics, and peerreviewed journals that regularly publish PK studies.
